Eupraxia Pharmaceuticals (EPRX) investor relations material

Technology and innovation

• DiffuSphere technology enables targeted, long-acting drug delivery directly into tissue, covered by five patent families.

• Fluticasone propionate is used as the active ingredient, targeting multiple inflammatory mediators in eosinophilic esophagitis (EoE).

• Delivery is performed during routine endoscopy, taking only a few minutes and causing minimal discomfort.

• The approach aligns with gastroenterologists’ practice models and offers a high-value commercial opportunity.

Clinical need and market landscape

• EoE prevalence is rising rapidly, with projections of 1 million patients in the US by 2030.

• Current long-term treatment is limited to weekly biologic injections, with poor compliance for daily oral medications.

• The new therapy is positioned as a second-line treatment after proton pump inhibitors.

• Compliance with existing oral medications is only about 30%.

Clinical trial data and efficacy

• Phase IIa trial shows a single injection achieves 40% clinical remission at two weeks, 60% at eight weeks, and 80% at six months, sustained up to one year.

• Higher doses and broader coverage improve outcomes in inflammation, fibrosis, and symptom relief.

• The therapy reverses esophageal fibrosis, not just halting progression but improving structural health.

• No correlation found between eosinophil reduction and symptom improvement; fibrosis and inflammation are better indicators.